САХАРНЫЙ ДИАБЕТ И COVID-19
Main Article Content
Аннотация:
Мы стремимся охватить большую часть текущих фактических данных о взаимном влиянии диабета и инфекции COVID-19 друг на друга и о ведении пациентов с COVID-19 с диабетом.
Ключевые слова:
Article Details
Как цитировать:
Библиографические ссылки:
Elamari S., et al. Characteristics and outcomes of diabetic patients infected by the SARS-CoV-2. The Pan African medical journal. 2020;37 32-32. [PMC free article] [PubMed] [Google Scholar]
Ceriello A. Hyperglycemia and COVID-19: what was known and what is really new? Diabetes Res Clin Pract. 2020;167 108383-108383. [PMC free article] [PubMed] [Google Scholar]
Nassar M., et al. Diabetes & metabolic syndrome. Clinical Research & Reviews; 2021. COVID-19 vaccine-induced myocarditis case report with literature review; p. 102205. [PMC free article] [PubMed] [Google Scholar]
Sterne J.A.C., et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. 2020;324(13):1330–1341. [PMC free article] [PubMed] [Google Scholar]
Alessi J., et al. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndrome. 2020;12:80. [PMC free article] [PubMed] [Google Scholar]
Di Dalmazi G., et al. Comparison of the effects of lockdown due to COVID-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study. BMJ open diabetes research & care. 2020;8(2) [PMC free article] [PubMed] [Google Scholar]
Biancalana E., et al. Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study. Acta Diabetol. 2020:1–6. [PMC free article] [PubMed] [Google Scholar]
Lim S., et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. [PMC free article] [PubMed] [Google Scholar]
Ceriello A. Hyperglycemia and COVID-19: what was known and what is really new? Diabetes Res Clin Pract. 2020;167:108383. [PMC free article] [PubMed] [Google Scholar]
Petrie J.R., Guzik T.J., Touyz R.M. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–584. [PMC free article] [PubMed] [Google Scholar]
Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070. [PMC free article] [PubMed] [Google Scholar]
Berbudi A., et al. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442–449. [PMC free article] [PubMed] [Google Scholar]
Šestan M., et al. Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity. 2018;49(1):164–177.e6. [PubMed] [Google Scholar]
Chen J., et al. The impact of COVID-19 on blood glucose: a systematic review and meta-analysis. Front Endocrinol. 2020;11(732) [PMC free article] [PubMed] [Google Scholar]
Chatterjee S., et al. COVID-19: the endocrine opportunity in a pandemic. Minerva Endocrinol. 2020;45(3):204–227. [PubMed] [Google Scholar]
Lippi G., Sanchis-Gomar F., Henry B.M. Response to: is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity? J Diabetes. 2021;13(2):179–180. [PubMed] [Google Scholar]
Scheen A.J., Marre M., Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and other recent reports. Diabetes Metab. 2020;46(4):265–271. [PMC free article] [PubMed] [Google Scholar]
Wang X., et al. Impacts of type 2 diabetes on disease severity, therapeutic effect, and mortality of patients with COVID-19. J Clin Endocrinol Metab. 2020;105(12) [PMC free article] [PubMed] [Google Scholar]
Moon S.J., et al. Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: a nationwide cohort study. Diabetes & metabolism journal. 2020;44(5):737–746. [PMC free article] [PubMed] [Google Scholar]
Alvarado-Vasquez N. Could a family history of type 2 diabetes be a risk factor to the endothelial damage in the patient with COVID-19? Med Hypotheses. 2020;146 110378-110378. [PMC free article] [PubMed] [Google Scholar]
Singh A.K., et al. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: a Critical Appraisal of Literature. Diabetes Metab Syndr. 2021;15(1):159–167. [PMC free article] [PubMed] [Google Scholar]
Lim S., et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. [PMC free article] [PubMed] [Google Scholar]
Hansen T.K., et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88(3):1082–1088. [PubMed] [Google Scholar]
Longo M., et al. Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovasc Diabetol. 2020;19(1):115. [PMC free article] [PubMed] [Google Scholar]
Organization, W.H. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. https://covid19.who.int/. 2020 [cited 2020 12/12]; Available from: https://covid19.who.int/.
Bode B., et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–821. [PMC free article] [PubMed] [Google Scholar]
Wang S., et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102–2111. [PMC free article] [PubMed] [Google Scholar]
Zhu L., et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabol. 2020;31(6):1068–1077.e3. [PMC free article] [PubMed] [Google Scholar]
Wang D., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. J Am Med Assoc. 2020;323(11):1061–1069. [PMC free article] [PubMed] [Google Scholar]
Lee M.H., et al. Effects of hyperglycaemia on complications of COVID-19: a meta-analysis of observational studies. Diabetes Obes Metabol. 2021;23(1):287–289. [PubMed] [Google Scholar]
Hwang J.L., Weiss R.E. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96–102. [PMC free article] [PubMed] [Google Scholar]
Nassar M., et al. Current systematic reviews and meta-analyses of COVID-19. World J Virol. 2021;10(4):182–208. [PMC free article] [PubMed] [Google Scholar]
Arabi Y.M., et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767. [PubMed] [Google Scholar]
Horby P., et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020;383(21):2030–2040. [PMC free article] [PubMed] [Google Scholar]
Chen Y., et al. Clinical characteristics and outcomes of type 2 diabetes patients infected with COVID-19: a retrospective study. Engineering. 2020;6(10):1170–1177. [PMC free article] [PubMed] [Google Scholar]
Bhatt K., et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1) [PMC free article] [PubMed] [Google Scholar]
Song G., Liang G., Liu W. Fungal Co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020;185(4):599–606. [PMC free article] [PubMed] [Google Scholar]
Heaney A.K., et al. Coccidioidomycosis and COVID-19 Co-infection, United States, 2020. Emerg Infect Dis. 2021;27(5):1266–1273. [PMC free article] [PubMed] [Google Scholar]
Alosaimi B., et al. Influenza co-infection associated with severity and mortality in COVID-19 patients. Virol J. 2021;18(1):127. [PMC free article] [PubMed] [Google Scholar]
Singh A.K., et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4) [PMC free article] [PubMed] [Google Scholar]
Ghosh A., Gupta R., Misra A. Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: guidelines for physicians. Diabetes Metab Syndr. 2020;14(4):273–276. [PMC free article] [PubMed] [Google Scholar]
Services., U.S.D.o.H.H . 2020. OCR announces notification of enforcement discretion for telehealth remote communications during the COVID-19 Nationwide Public Health Emergency.https://www.hhs.gov/about/news/2020/03/17/ocr-announces-notification-of-enforcementdiscretion-for-telehealth-remote-communications-during-thecovid-19.html 2020]; Available from: [Google Scholar]
Charles B.L. Telemedicine can lower costs and improve access. Healthc Financ Manag. 2000;54(4):66–69. [PubMed] [Google Scholar]
Tchero H., et al. Clinical effectiveness of telemedicine in diabetes mellitus: a meta-analysis of 42 randomized controlled trials. Telemed J e Health. 2019;25(7):569–583. [PubMed] [Google Scholar]